Table 1.
Baseline characteristics of the 48 patients
| Characteristics | Rifampin group (n = 23) | Monotherapy group (n = 25) | Total (n = 48) |
|---|---|---|---|
| Age, year, median (range) | 70 (37–92) | 66 (39–84) | 68.5 (37–92) |
| Sex, male (%) | 15 (65) | 17 (68) | 32 (67) |
| ASA scores 1–2, no (%) | 16 (70) | 21 (84) | 37 (77) |
| BMI, mean (SD) | 30.1 (1.3) | 27 (1.0) | 28.4 (0.8) |
| Diabetes mellitus | 3 | 3 | 6 |
| Immunosuppressive medication | 2 | 2 | 4 |
| Smoking | 3 | 4 | 7 |
| Time from index surgery to revision, median, days (range) | 19 (7–912) | 17 (8–122) | 18 (7–912) |
| Hip prosthesis | |||
| Primary hip prosthesis | 17 | 14 | 31 |
| Revision hip prostehesis | 3 | 5 | 8 |
| Knee prosthesis | |||
| Primary knee prosthesis | 3 | 6 | 9 |
| CRP pre surgery, mean (SD) | 135 (21.1) | 167 (26.4) | 151 (16.9) |
| Creatinin pre surgery, mean (SD) | 78 (5.7) | 79 (4.4) | 79 (3.5) |
| Type of prosthesisa | |||
| Cemented prosthesis | 14 | 16 | 30 |
| Non cemented | 4 | 5 | 9 |
| Reverse hybrid | 4 | 4 | 8 |
ASA American Society of Anesthesiologists physical status classifications system, BMI body mass index
aMissing data, n = 1